



In association with



## CLEVELAND CLINIC ADVANCED CERTIFICATE COURSE IN DIABETES 2020

&

## EASD DIABETES SYMPOSIUM SCIENTIFIC PROGRAM

29 AUGUST 2020 Time zone (GMT+5.30)		CCACCD DAY 1	SPEAKER	MODERATOR
CLEVELAND TIME	INDIA TIME			
<b>SESSION 1 4.30-7.15AM</b>	<b>SESSION 1 2.00-4.45PM</b>	<b>Opening Remarks And Introduction- 15 Minutes</b>	<b>BM Makkar</b>	
4.45-5.15AM	2.15-2.45pm	Nutritional Management in Diabetes	Shashank Joshi	Banshi Saboo Rajiv Kovil Neeta Deshpande
5.15-5.45AM	2.45-3.15pm	Diabetes Paradoxes	Anil Bhansali	
5.45-6.15AM	3.15-3.45pm	Metabolic Flexibility	BM Makkar	
6.15-6.45AM	3.45-4.15pm	Diabetes And COVID	Shashank Joshi	
6.45-7.15AM	4.15-4.45pm	DISCUSSION		

<b>7.15-7.30AM</b>	<b>4.45-5.00PM</b>	<b>Opening Remarks And Introduction</b>	<b>Cleveland Faculty</b>	
<b>PLENARY SESSION 1</b> <b>7.30-8.00AM</b>	<b>PLENARY SESSION 1</b> <b>5.00-5.30PM</b>	<b>Hypertriglyceridemia And CV Risk – Back In Action</b>	<b>Adi Mehta</b>	Sanjay Agarwal Manoj Chawla
<b>DEBATE 1</b> <b>8.00-8.30AM</b>	<b>DEBATE 1</b> <b>5.30-6.00PM</b>	<b>WHAT IS PRIMARY IN DIABETES MANAGEMENT</b> <b>ASCVD Risk Reduction Is Primary - Hyperglycemia Management Is Primary –</b>	<b>R Chawla</b> <b>BM Makkar</b>	Adi Mehta Robert Zimmerman
<b>ESC LIVE SESSION</b> <b>8.30-9.15AM</b>	<b>ESC LIVE SESSION</b> <b>6.00-6.45PM</b>	<b>EMPEROR-Reduced: Empagliflozin in Heart Failure With a Reduced Ejection Fraction, With and Without Diabetes</b>	<b>Live Webcast from ESC</b>	Balbir Singh SR Aravind
	<b>DISCUSSION</b>	<b>CLEVELAND CLINIC FACULTY+</b>		
<b>PLENARY SESSION 2</b> <b>9.15-9.45AM</b>	<b>PLENARY SESSION 2</b> <b>6.45-7.15PM</b>	<b>Type 2 Diabetes Is Not One Disease: New Evidence From Clustering Of Diabetes In India</b>	<b>V Mohan</b>	Adi Mehta Mario Skugor
<b>SESSION 2</b> <b>9.45-11.15AM</b>	<b>SESSION 2</b> <b>7.15-8.30PM</b>	<b>ONGOING LEARNINGS FROM LANDMARK TRIALS</b>		AK Das Vijay Panikar Purvi Chawla
9.45-10.00AM	7.15-7.30PM	DCCT/EDIC	Robert Zimmerman	AK Das Vijay Panikar Purvi Chawla
10.00-10.15AM	7.30-7.45PM	UKPDS	Mario Skugor	
10.15-10.30AM	7.45-8.00PM	Legacy Effect – What Have We Learnt?	Adi Mehta	
10.30-10.45AM	8.00-8.15PM	TEDDY & T1GER	Robert Zimmerman	

10.45-11.00AM	8.15-8.30PM	VERIFY	Melissa Li-Ng	
11.00-11.15AM	8.30-8.45PM	DISCUSSION		
<b>SESSION 3</b> <b>11.15AM-12.30PM</b>	<b>SESSION 3</b> <b>8.45-10.00PM</b>	<b>PAST, PRESENT, FUTURE</b>		JK Sharma Dheeraj Kapoor
11.15-11.35AM	8.45-9.05PM	Sulfonylureas	Melissa Li Ng	JK Sharma Dheeraj Kapoor
11.35-11.55AM	9.05-9.25PM	Pioglitazone	Adi Mehta	
11.55AM-12.15PM	9.25-9.45PM	DPP4 Inhibitors	Mario Skugor	
12.15-12.30PM	9.45-10.00PM	DISCUSSION		

<b>30 AUGUST 2020</b> <b>TIME ZONE (GMT+5.30)</b>		<b>CCACCD DAY 2</b>		<b>SPEAKER</b>	<b>MODERATOR</b>
<b>WORKSHOPS</b>					
<b>CLEVELAND TIME</b>	<b>INDIA TIME</b>				
3.30-4.30AM	11.00AM-12.00PM	Point of Care Testing		Rajeev Chawla	
4.30-5.30AM	12.00-1.00PM	Glucose Monitoring Technologies – What Works for India?		Jothydev Kesavdev	
5.30-6.30AM	1.00-2.00PM	WORKSHOP OF TIR/GLYCEMIC VARIABILITY – NOVO NORDISK		Jothydev Kesavdev Manoj Chawla	
<b>UK TIME</b> <b>9.30AM-12.15PM</b>	<b>INDIA TIME</b> <b>2.00-4.45PM</b>	<b>EASD DIABETES SYMPOSIUM</b>			
9.30-10.00AM	2.00-2.30PM	SGLT2 Inhibitors – Are They All Same?		Leszek Czupryniak	

10.00-10.30AM	2.30-3.00PM	Real World Data From 2nd Generation Basal Insulins - Are They Worth It	Dídac Mauricio	Banshi Saboo Neeta Deshpande
10.30-11.00AM	3.00-3.30PM	Update On Closed Loop Systems For Type 1 Diabetes	Pratik Choudhary	
11.00-11.30AM	3.30-4.00PM	Prevention of Type 1 Diabetes	Chantal Mathieu	
11.30-11.45AM	4.00-4.15PM	DISCUSSION		
11.45AM-12.15PM	4.15-4.45.00PM	PANEL DISCUSSION – Barriers To Adoption Of Technologies For Diabetes Management In India	EASD Faculty	Banshi Saboo, Neeta Deshpande, Jothydev, Manoj Chawla, Rajeev Kovil
<b>5.00PM-10.00PM (GMT+5.30)</b>		<b>CCACCD DAY2</b>		
<b>CLEVELAND TIME</b>	<b>INDIA TIME</b>			
7.15AM-7.30AM	4.45-5.00PM	RECAP OF DAY 1		BM Makkar
<b>SESSION 4 7.30AM-8.45AM</b>	<b>SESSION 4 5.00-6.15PM</b>	<b>SGLT2 Inhibitors Update</b>		Sanjay Agarwal Shalini Jaggi
7.30-7.45AM	5.00-5.15PM	CREDENCE – Changing Diabetes Management Perspective	Melissa Li Ng	Sanjay Agarwal Shalini Jaggi
7.45-8.00AM	5.15-5.30PM	DECLARE to DAPA HF – Dapagliflozin Hence Forth	Adi Mehta	
8.00-8.15AM	5.30-5.45PM	EMPA-REG and Onwards	Mario Skugor	
8.15-8.30AM	5.45-6.00PM	Gliflozins – What's New?	Robert Zimmerman	
8.30-8.45AM	6.00-6.15PM	DISCUSSION		
<b>PLENARY SESSION 3 8.45AM-9.15AM</b>	<b>PLENARY SESSION 3 6.15-6.45PM</b>	<b>Future Of Insulin Therapy</b>	<b>Robert Zimmerman</b>	Sunil Gupta Girish Khurana

<b>SESSION 5</b> <b>9.15AM-10.30AM</b>	<b>SESSION 5</b> <b>6.45-8.00PM</b>			
9.15-9.35AM	6.45-7.05PM	Basal Insulin Analogues – Have They Revolutionized Insulin Therapy?	Adi Mehta	Arvind Gupta Amit Gupta
9.35-9.55AM	7.05-7.25PM	Weight Centric Management Of Diabetes	Mario Skugor	
9.55-10.15AM	7.25-7.45PM	Determining CV risk in Clinical Practice	Melissa Li Ng	
10.15-10.30AM	7.45-8.00PM	DISCUSSION		
<b>DEBATE</b> <b>10.30AM-11.15AM</b>	<b>DEBATE</b> <b>8.00-8.45PM</b>	<b>Metformin Should Be Considered First Line Therapy For Diabetes Patients With ASCVD/At High Risk Of ASCVD.</b>	<b>No – Adi Mehta</b> <b>Yes – BM Makkar</b>	SR Aravind Hemant Thacker
<b>SESSION 6</b> <b>11.15AM-12.30PM</b>	<b>SESSION 6</b> <b>8.45-10.00PM</b>			
11.15-11.35AM	8.45-9.05PM	Cardio-Renal Risk Reduction In Diabetes – Changing Paradigm	Melissa Li Ng	Anuj Maheshwari Vipul Gupta
11.35-11.55AM	9.05-9.25PM	New GLP1 RAs – Are They Different	Mario Skugor	
11.55AM-12.15PM	9.25-9.45PM	Newer Glucose Sensing Technologies	Robert Zimmerman	
12.15-12.30PM	9.45-10.00PM	DISCUSSION		
<b>12.30PM-12.45PM</b>	<b>10.00-10.15PM</b>	<b>CLOSING REMARKS</b>		Cleveland Faculty